5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives

Details 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives

2007-11-06

2007-11-06

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S135000

Reexamination Certificate

active

10510026

ABSTRACT:
Compounds of the formulaprovide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula I may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

REFERENCES:
patent: 5162340 (1992-11-01), Chakravarty et al.
patent: 5281614 (1994-01-01), Ashton et al.
patent: 5412097 (1995-05-01), Chakravarty et al.
patent: 5958957 (1999-09-01), Anderson et al.
patent: 5972978 (1999-10-01), Anderson et al.
patent: 6063800 (2000-05-01), Anderson et al.
patent: 6080770 (2000-06-01), Anderson et al.
patent: 501568 (1992-09-01), None
patent: 0 512 870 (1992-11-01), None
patent: WO92/20687 (1992-11-01), None
patent: WO97/40017 (1997-10-01), None
patent: WO 01/19831 (2001-03-01), None
Groutas et al. “Inhibition of Serine Proteases by Functionalized Sulfonamides Coupled to the 1,2,5-thiadiazolidin-3-one 1,1 Dioxide Scaffold” Bioorganic and Medicinal Chemistry, 2001, vol. 9, pp. 1543-1548.
Albericio et al., “Synthesis of a Sulfahydantoin Library”, J. Comb. Chem. vol. 3, pp. 290-300 (2001).
Bright et al., “Competitive particle concentration fluorescence immunoassays for measuring antidiabetic drug levels in mouse plasma” Journal of Immunological Methods, vol. 207, pp. 23-31(1997).
Abstract , Eberle et al., Preparation of microbiocidal N-phenyl-N [4- (-pyridyl)-pyrimidin-2-yl) amines.
Ducry et al., “Synthesis of 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Derivatives and evaluation of their affinity for MHC Class-II Proteins”, Helvetica Chimica, Acta, vol. 82, No. 12, pp. 2432-2447 (1999).
Mantegani et al., “Synthesis and Antihypertensive Activity of 2,4-dioxoimidazolidin-1yl and perhydro-2,4-dioxopyrimidin-1-yl ergoline derivatives”, IL FARMACO, vol. 53, pp. 293-304 (1998).

Affiliated with

Also associated with

Rating

5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3880189